相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
Hyuna Sung et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2021)
Adding Ovarian Suppression to Tamoxifen for Premenopausal Breast Cancer: A Randomized Phase III Trial
Hyun-Ah Kim et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Tailoring Adjuvant Endocrine Therapy for Premenopausal Breast Cancer
P. A. Francis et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Absolute Benefit of Adjuvant Endocrine Therapies for Premenopausal Women With Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Early Breast Cancer: TEXT and SOFT Trials
Meredith M. Regan et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Adjuvant Endocrine Therapy for Women With Hormone Receptor-Positive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update on Ovarian Suppression
Harold J. Burstein et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Adjuvant Ovarian Suppression in Premenopausal Breast Cancer
Prudence A. Francis et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Zoledronic acid combined with adjuvant endocrine therapy of tamoxifen versus anastrozol plus ovarian function suppression in premenopausal early breast cancer: final analysis of the Austrian Breast and Colorectal Cancer Study Group Trial 12
M. Gnant et al.
ANNALS OF ONCOLOGY (2015)
The Japanese Breast Cancer Society Clinical Practice Guideline for systemic treatment of breast cancer
Hirofumi Mukai et al.
BREAST CANCER (2015)
Gonadotropin-releasing hormone analogues for the prevention of chemotherapy-induced premature ovarian failure in cancer women: Systematic review and meta-analysis of randomized trials
Lucia Del Mastro et al.
CANCER TREATMENT REVIEWS (2014)
Combined Cancer Therapy: Strategies to Overcome Acquired Aromatase Inhibitor Resistance
Susan B. Kesmodel et al.
CURRENT PHARMACEUTICAL DESIGN (2014)
Phase III Comparison of Tamoxifen Versus Tamoxifen Plus Ovarian Function Suppression in Premenopausal Women With Node-Negative, Hormone Receptor-Positive Breast Cancer (E-3193, INT-0142): A Trial of the Eastern Cooperative Oncology Group
Amye J. Tevaarwerk et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Adjuvant Exemestane with Ovarian Suppression in Premenopausal Breast Cancer
Olivia Pagani et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Network Meta-Analysis Using R: A Review of Currently Available Automated Packages
Binod Neupane et al.
PLOS ONE (2014)
Analysis of Ki-67 expression with neoadjuvant anastrozole or tamoxifen in patients receiving goserelin for premenopausal breast cancer
Hiroji Iwata et al.
CANCER (2013)
Efficacy of goserelin plus anastrozole in premenopausal women with advanced or recurrent breast cancer refractory to an LH-RH analogue with tamoxifen: Results of the JMTO BC08-01 phase II trial
Reiki Nishimura et al.
ONCOLOGY REPORTS (2013)
The Comprehensive R Archive Network
Kurt Hornik
WILEY INTERDISCIPLINARY REVIEWS-COMPUTATIONAL STATISTICS (2012)
Interaction between goserelin and tamoxifen in a prospective randomised clinical trial of adjuvant endocrine therapy in premenopausal breast cancer
Asgerdur Sverrisdottir et al.
BREAST CANCER RESEARCH AND TREATMENT (2011)
Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 62-month follow-up from the ABCSG-12 randomised trial
Michael Gnant et al.
LANCET ONCOLOGY (2011)
Adjuvant© Online estimation of chemotherapy effectiveness when added to ovarian function suppression plus tamoxifen for premenopausal women with estrogen-receptor-positive breast cancer
Robert J. Paridaens et al.
BREAST CANCER RESEARCH AND TREATMENT (2010)
Phase II Trial of Anastrozole Plus Goserelin in the Treatment of Hormone Receptor-Positive, Metastatic Carcinoma of the Breast in Premenopausal Women
Robert W. Carlson et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Long-term Effectiveness of Adjuvant Goserelin in Premenopausal Women With Early Breast Cancer
Allan Hackshaw et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2009)
Aromatase inhibitors: Are there differences between steroidal and nonsteroidal aromatase inhibitors and do they matter?
William R. Miller et al.
ONCOLOGIST (2008)
A randomised trial of goserelin versus control after adjuvant, risk-adapted chemotherapy in premenopausal patients with primary breast cancer - GABG-IV B-93
Manfred Kaufmann et al.
EUROPEAN JOURNAL OF CANCER (2007)
Antitumour and biological effects of letrozole and GnRH analogue as primary therapy in premenopausal women with ER and PgR positive locally advanced operable breast cancer
R. Torrisi et al.
BRITISH JOURNAL OF CANCER (2007)
Ovarian ablation or suppression in premenopausal early breast cancer: Results from the international adjuvant breast cancer ovarian ablation or suppression randomized trial
J. M. Bliss et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2007)
Zoledronic acid prevents cancer treatment-induced bone loss in premenopausal women receiving adjuvant endocrine therapy for hormone-responsive breast cancer: A report from the Austrian Breast and Colorectal Cancer Study Group
Michael F. X. Gnant et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Molecular basis for the aromatization reaction and exemestane-mediated irreversible inhibition of human aromatase
Yanyan Hong et al.
MOLECULAR ENDOCRINOLOGY (2007)
CMF versus goserelin as adjuvant therapy for node-negative, hormone-receptor-positive breast cancer in premenopausal patients: A randomised trial (GABG trial IV-A-93)
Gunter von Minckwitz et al.
EUROPEAN JOURNAL OF CANCER (2006)
Complete hormonal blockade versus epirubicin-based chemotherapy in premenopausal, one to three node-positive, and hormone-receptor positive, early breast cancer patients:: 7-year follow-up results of French Adjuvant Study Group 06 randomised trial
H. Roche et al.
ANNALS OF ONCOLOGY (2006)
Adjuvant goserelin in pre-menopausal patients with early breast cancer: Results from the ZIPP study
M. Baum et al.
EUROPEAN JOURNAL OF CANCER (2006)
Tamoxifen after adjuvant chemotherapy for premenopausal women with lymph node-positive breast cancer: International Breast Cancer Study Group Trial 13-93
M Colleoni et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival:: an overview of the randomised trials
O Abe et al.
LANCET (2005)
Chemoendocrine therapy for premenopausal women with axillary lymph node-positive, steroid hormone receptor-positive breast cancer: Results from INT 0101 (E5188)
NE Davidson et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival:: an overview of the randomised trials
O Abe et al.
LANCET (2005)
Randomized trial of adjuvant ovarian suppression in 926 premenopausal patients with early breast cancer treated with adjuvant chemotherapy
R Arriagada et al.
ANNALS OF ONCOLOGY (2005)
A randomised factorial trial of sequential doxorubicin and CMF vs CMF and chemotherapy alone vs chemotherapy followed by goserelin plus tamoxifen as adjuvant treatment of node-positive breast cancer
S De Placido et al.
BRITISH JOURNAL OF CANCER (2005)
Adjuvant chemotherapy followed by goserelin versus either modality alone for premenopausal lymph node-negative breast cancer: A randomized trial
M Castiglione-Gertsch et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2003)
Quality of life in goserelin-treated versus cyclophosphamide plus methotrexate plus fluorouracil-treated premenopausal and perimenopausal patients with node-positive, early breast cancer: The Zoladex Early Breast Cancer Research Association Trialists Group
H de Haes et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
High p27Kip1 expression predicts superior relapse-free and overall survival for premenopausal women with early-stage breast cancer receiving adjuvant treatment with tamoxifen plus goserelin
G Pohl et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
Survival analyses from the ZEBRA study:: goserelin (Zoladex™) versus CMF in premenopausal women with node-positive breast cancer
M Kaufmann et al.
EUROPEAN JOURNAL OF CANCER (2003)
The use of gonadotrophin-releasing hormone (GnRH) agonists in early and advanced breast cancer in pre- and perimenopausal women
JFR Robertson et al.
EUROPEAN JOURNAL OF CANCER (2003)
Randomized adjuvant trial of tamoxifen and goserelin versus cyclophosphamide, methotrexate, and fluorouracil: Evidence for the superiority of treatment with endocrine blockade in premenopausal patients with hormone-responsive breast cancer - Austrian Breast and Colorectal Cancer Study Group Trial 5
R Jakesz et al.
JOURNAL OF CLINICAL ONCOLOGY (2002)
Goserelin versus cyclophosphamide, methotrexate, and fluorouracil as adjuvant therapy in premenopausal patients with node-positive breast cancer: The Zoladex Early Breast Cancer Research Association Study
W Jonat et al.
JOURNAL OF CLINICAL ONCOLOGY (2002)
Adjuvant endocrine treatment (goserelin vs tamoxifen) in pre-menopausal patients with operable node positive stage II breast cancer.: A prospective randomized national multicenter study
JA Söreide et al.
EUROPEAN JOURNAL OF SURGICAL ONCOLOGY (2002)
Cyclophosphamide, methotrexate, and fluorouracil versus tamoxifen plus ovarian suppression as adjuvant treatment of estrogen receptor-positive pre-/perimenopausal breast cancer patients: Results of the Italian Breast Cancer Adjuvant Study Group 02 Randomized Trial
F Boccardo et al.
JOURNAL OF CLINICAL ONCOLOGY (2000)
Combined treatment with buserelin and tamoxifen in premenopausal metastatic breast cancer: A randomized study
JGM Klijn et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2000)
分享论文
